Latest Safety News

St Barbara Limited reported a $52 million underlying loss for FY25, driven by investments in its Simberi Expansion Project and operational challenges. The company classified its Atlantic operations as discontinued, recognizing a $38 million impairment, while completing a $100 million capital raise to support growth.

Super Retail Group delivered record sales growth in FY25 despite margin pressures, expanded its store network, and boosted loyalty membership, while declaring a special dividend alongside its final payout.

Super Retail Group reported record FY25 sales of AUD 4.07 billion, driven by store expansion and online growth, while statutory net profit declined 7.6% amid margin and cost pressures. The Board signals a strategic review to guide growth through 2030.

Prescient Therapeutics reported an 11.1% reduction in net loss for FY2025, progressing its lead candidate PTX-100 into Phase 2a trials with FDA Fast Track and Orphan Drug designations, supported by a recent $9.8 million capital raise.

Alliance Aviation Services Limited reported a 19% revenue increase to $760.9 million in FY2025, while net profit after tax slipped 5% to $57.3 million amid operational challenges. The company declared a fully franked dividend of 3.0 cents per share and expanded its fleet to 79 aircraft.

Saunders International reported a modest revenue dip and sharp profit decline in FY2025, offset by a transformative acquisition that expands its water infrastructure footprint and doubles its project pipeline.

Magnetite Mines has launched a $2.65 million renounceable rights issue with increased underwriting support, following promising rare earth mineralisation findings at its Ironback Hill Project.

Saunders International reported a slight revenue dip and a sharp EBITDA decline in FY2025, offset by a transformative acquisition that dramatically expands its order book and pipeline.

Invion Limited secures a pivotal FDA Orphan Drug Designation for its lead candidate INV043, targeting anal cancer with promising preclinical results and a fast-tracked development path.

Neurizon Therapeutics reports encouraging topline results from its Phase 1 Open-Label Extension study of NUZ-001, demonstrating long-term safety and a significant survival advantage in ALS patients. These findings pave the way for the pivotal HEALEY ALS Platform Trial planned for late 2025.

Monash IVF Group has completed an independent review into two separate clinic incidents involving non-standard IVF treatments, revealing human errors and IT system issues. The company commits to enhanced safeguards without expecting significant financial impact.

LTR Pharma’s intranasal ED treatment SPONTAN achieves peak effect up to five times faster than oral tablets, according to new peer-reviewed clinical data published in a leading European journal.